Flunitrazepam

證據等級: L5

預測適應症: 10 個

Flunitrazepam: From Sedative-Hypnotic to Insomnia

One-Sentence Summary

Flunitrazepam (Rohypnol) is a high-potency benzodiazepine historically approved in several European countries as a sedative-hypnotic during the 1970s–1990s, but currently not marketed in the Netherlands and carrying no CBG-MEB authorization. The TxGNN model predicts it may be effective for Insomnia, with 1 clinical trial and 11 publications currently supporting this direction — though this largely confirms established pharmacology rather than identifying a genuinely novel repurposing target. A secondary finding of independent clinical interest is the prediction for Alcohol Withdrawal Delirium (Rank 6, Evidence Level L3), which is supported by direct clinical evidence from ICU practice.

Quick Overview

Item	Content
Original Indication	Sedative-hypnotic; historically approved in Europe for insomnia and procedural sedation (1970s–1990s)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.89%
Evidence Level	L3
NL Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, flunitrazepam belongs to the 1,4-benzodiazepine class and acts as a positive allosteric modulator of the GABA-A receptor at the benzodiazepine binding site. By increasing the frequency of chloride ion channel opening in response to GABA, it suppresses central nervous system over-excitation — the direct pharmacological basis for sedation, muscle relaxation, anxiolysis, and hypnosis. At approximately 5–10 times the potency of diazepam, its sleep-promoting effects are among the most pronounced within the benzodiazepine class.

The TxGNN prediction for insomnia is therefore not a novel repurposing hypothesis but a validation of the drug’s own historical approved indication. Multiple sleep laboratory and comparative clinical studies have confirmed flunitrazepam’s efficacy in reducing sleep latency, increasing Stage 2 sleep duration, and improving subjective sleep quality (PMID 8519370, PMID 14722706). A large-scale randomised study comparing flunitrazepam, zopiclone, triazolam, and placebo across 1,507 insomniac patients further documented its clinical effectiveness. Importantly, rebound insomnia upon withdrawal — a known class effect — has also been specifically characterised for flunitrazepam (PMID 430730, PMID 684426), highlighting the risk-benefit complexity of its use.

The clinical development context has, however, fundamentally changed since the drug’s European approval era. Due to its extreme abuse potential as a drug used in drug-facilitated sexual assault, high physical dependence liability, anterograde amnesic effects, and dangerous interaction with alcohol, flunitrazepam has been withdrawn or severely restricted across most jurisdictions. In the Netherlands, it holds no CBG-MEB authorisation and is not commercially available. Any development pathway for insomnia faces an insurmountable regulatory and public safety barrier, given the ready availability of multiple safer registered alternatives (temazepam, zolpidem, zopiclone).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02648776	N/A	Unknown	1,400	Prospective cohort study at a Taiwanese academic medical centre assessing risk-benefit of hypnotic agents in elderly patients with sleep disorders. Examines medication use patterns, pharmacokinetic/pharmacogenetic characteristics, and clinical, economic, and humanistic outcomes. Flunitrazepam is not explicitly listed as a primary study drug; relevance is at benzodiazepine class level only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20171127	2010	Comparative Clinical Study	Sleep Medicine Reviews	Systematic review of hypnotic drugs’ effects on body balance and standing steadiness; flunitrazepam implicated in fall risk and hip fractures when patients wake at night or in the morning
8519370	1993	Comparative Clinical Study	European Respiratory Journal	Compared single doses of zolpidem 10 mg, triazolam 0.25 mg, and flunitrazepam 1 mg in 12 hypercapnic severe COPD patients complaining of insomnia; assessed arterial blood gases and breathing control alongside hypnotic efficacy
2883822	1986	Clinical Review	Acta Psychiatrica Scandinavica (Supplement)	Reviewed pharmacodynamic changes in benzodiazepines during normal ageing; controlled studies with diazepam, temazepam, nitrazepam, and flunitrazepam consistently showed 2–3 fold increased response in healthy elderly subjects
430730	1979	Clinical Observation	JAMA	Fifteen sleep laboratory studies evaluating five benzodiazepines including flunitrazepam; rebound insomnia (worsening of sleep vs. baseline) documented following withdrawal, attributed to short and intermediate half-lives
684426	1978	Clinical Observation	Science	First description of rebound insomnia as a new clinical syndrome following withdrawal of three benzodiazepine hypnotics including flunitrazepam; benzodiazepine receptor hypothesis proposed involving lag in endogenous ligand replacement
14722706	2004	Animal Study	Psychopharmacology	Evaluated flunitrazepam and two other hypnotics in a sleep-disturbed rat model; new sleep disturbance model validated for estimating hypnotic drug characteristics
6114852	1981	Drug Review	Drugs	Comprehensive review of triazolam pharmacological properties and therapeutic efficacy for insomnia; flunitrazepam discussed as a longer-acting comparator, with triazolam favoured due to shorter half-life and reduced next-day impairment
2883820	1986	Clinical Review	Acta Psychiatrica Scandinavica (Supplement)	Review of clinical indications for use of hypnotics and need for pharmacokinetic diversity; discusses positioning of flunitrazepam relative to other benzodiazepines based on elimination half-life and distribution profile

Netherlands Market Information

Flunitrazepam currently holds no CBG-MEB marketing authorizations in the Netherlands. There are no registered pharmaceutical products containing flunitrazepam available through Dutch dispensing channels, and no dosage forms are authorized for any route of administration.

Historically marketed as Rohypnol (Roche), flunitrazepam was available in a number of European countries as a short-term hypnotic during the 1970s and 1980s. It was subsequently withdrawn or severely restricted across EU member states following recognition of its abuse profile, its role in drug-facilitated sexual assault, and the availability of safer therapeutic alternatives. The drug does not appear in the Dutch RVG register and cannot be legally prescribed or dispensed through normal Dutch pharmacy channels.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information.

Regulatory note for the Netherlands context: While SmPC data is not available in this Evidence Pack, the following safety signals are well-documented in the retrieved literature and are critical to any assessment within the Dutch healthcare system:

Controlled substance: Flunitrazepam is subject to stringent narcotics control legislation in the Netherlands under the Opium Act (Opiumwet) and EU regulations

Abuse and drug-facilitated assault: Internationally recognised as a drug used in sexual assault contexts; quick onset of sedation and anterograde amnesia are documented at therapeutic doses

Physical dependence and rebound: High risk of dependence; rebound insomnia documented even after short-term single-nightly-dose administration (PMID 430730, PMID 684426)

CNS/respiratory depression: Potentially fatal when combined with alcohol or other CNS depressants; animal and clinical data confirm potentiation of depressant effects (PMID 38676788)

Paradoxical reactions: Agitation, disinhibition, aggressive behaviour, and loss of impulse control reported in a proportion of users (PMID 16087304)

Fall risk: Documented impairment of body balance and standing steadiness associated with fracture risk, especially in elderly patients (PMID 20171127)

Conclusion and Next Steps

Decision: Hold

Rationale: Flunitrazepam is not marketed in the Netherlands, carries zero CBG-MEB authorizations, and presents an extreme regulatory and public safety burden — including controlled substance scheduling, documented abuse as a date rape drug, and dependence liability — that renders clinical development for insomnia non-viable within the Dutch healthcare framework, particularly given the ready availability of safer registered alternatives.

To proceed with further assessment (for any indication), the following would be needed:

Full SmPC or equivalent product documentation, including contraindications, warnings, and drug interaction profile (via TFDA SmPC download or EMA historical assessment reports)
Mechanism of action confirmation via DrugBank API query (Data Gap DG002)
Regulatory feasibility consultation with CBG-MEB regarding controlled substance scheduling constraints for any proposed new indication
A clinical justification demonstrating superiority or differentiated benefit over currently registered benzodiazepines (temazepam, oxazepam, lorazepam) and non-benzodiazepine hypnotics (zolpidem, zopiclone) already authorized in the Netherlands
For the alcohol withdrawal delirium hypothesis specifically (Rank 6, L3 evidence): A structured systematic review of IV flunitrazepam vs. standard-of-care benzodiazepines in ICU settings, and a protocol assessment for prospective study feasibility under Dutch controlled substance regulations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.